Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
06 Aug 2024
Historique:
accepted: 02 08 2024
received: 17 04 2024
revised: 27 06 2024
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 6 8 2024
Statut: aheadofprint

Résumé

In radiotherapy (RT) for brain tumors, patient heterogeneity masks treatment effects, complicating the prediction and mitigation of radiation-induced brain necrosis. Therefore, understanding this heterogeneity is essential for improving outcome assessments and reducing toxicity. We developed a clinically practical pipeline to clarify the relationship between dosimetric features and outcomes by identifying key variables. We processed data from a cohort of 130 patients treated with proton therapy for brain and head and neck tumors, utilizing an expert-augmented Bayesian network to understand variable interdependencies and assess structural dependencies. Critical evaluation involved a 3-level grading system for each network connection and a Markov blanket analysis to identify variables directly impacting necrosis risk. Statistical assessments included log-likelihood ratio (LLR), integrated discrimination index (IDI), net reclassification index (NRI), and receiver operating characteristic (ROC). The analysis highlighted tumor location and proximity to critical structures like white matter and ventricles as major determinants of necrosis risk. The majority of network connections were clinically supported, with quantitative measures confirming the significance of these variables in patient stratification (LLR=12.17, p=0.016; IDI=0.15; NRI=0.74). The ROC curve area was 0.66, emphasizing the discriminative value of non-dosimetric variables. Key patient variables critical to understanding brain necrosis post-RT were identified, aiding the study of dosimetric impacts and providing treatment confounders and moderators. This pipeline aims to enhance outcome assessments by revealing at-risk patients, offering a versatile tool for broader applications in RT to improve treatment personalization in different disease sites.

Identifiants

pubmed: 39106090
pii: 746883
doi: 10.1158/1078-0432.CCR-24-1215
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Ibrahim Chamseddine (I)

Massachusetts General Hospital, Harvard Medical School, Boston, United States.

Keyur Shah (K)

Massachusetts General Hospital, Harvard Medical School, Boston, United States.

Hoyeon Lee (H)

Massachusetts General Hospital, Harvard Medical School, Boston, United States.

Felix Ehret (F)

Massachusetts General Hospital, Boston, MA, United States.

Jan Schuemann (J)

Massachusetts General Hospital, Boston, United States.

Alejandro Bertolet (A)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Helen A Shih (HA)

Massachusetts General Hospital, Boston, MA, United States.

Harald Paganetti (H)

Massachusetts General Hospital, Boston, MA, United States.

Classifications MeSH